Adjuvant HER2/neu peptide cancer vaccines in breast cancer

被引：34
|
作者：
Clifton, Guy T. [1 ]
Mittendorf, Elizabeth A. [2 ]
Peoples, George E. [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[3] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA
来源：
IMMUNOTHERAPY | 2015年 / 7卷 / 11期
关键词：
AE37; breast cancer; cancer vaccine; E75; GP2; immunotherapy; peptide; COLONY-STIMULATING FACTOR; GROUP-STUDY I-01; I CLINICAL-TRIAL; E75; VACCINE; PHASE-I; BOOSTER INOCULATIONS; CTL EPITOPES; IMMUNOTHERAPY; RECURRENCE; CELLS;
D O I：
10.2217/imt.15.81
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Active cancer immunotherapy remains an exciting and rapidly advancing field in oncology. Peptide cancer vaccines are an attractive therapeutic option as they are safe and easily produced and administered. Peptide cancer vaccines may be most effective in patients with a lower disease burden, when cancer tolerance is minimized. Our experience with three peptide cancer vaccines, E75, GP2 and AE37, in clinically disease-free breast cancer patients provides encouraging results that this method may be effective. Furthermore, the combined results of the initial trials suggest that the vaccine administered may need to be tailored to the specific subtype of cancer and tumor antigen expression level to achieve maximum effectiveness. The results also suggest that combining peptide vaccines with other immunotherapy may lead to a synergistic effect.
引用
收藏
页码：1159 / 1168
页数：10
相关论文
共 50 条
  • [21] Adjuvant trastuzumab for breast cancer - Assessing HER2/neu status incurs more costs for treatment
    Kell, MR
    Power, CP
    [J]. BRITISH MEDICAL JOURNAL, 2005, 331 (7526): : 1202 - 1202
  • [22] Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
    Wiedermann, Ursula
    Davis, Adam B.
    Zielinski, Christoph C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (01) : 1 - 12
  • [23] Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
    Ursula Wiedermann
    Adam B. Davis
    Christoph C. Zielinski
    [J]. Breast Cancer Research and Treatment, 2013, 138 : 1 - 12
  • [24] Serum HER2/neu levels in breast cancer patients with different level of tumor HER2/neu protein expression
    Kushlinsky, Nicolai
    Gershtein, Elena
    Shyroky, Vyacheslav
    Ermilova, Valeriya
    Tchemeris, Galina
    Letyagin, Victor
    [J]. TUMOR BIOLOGY, 2007, 28 : 95 - 95
  • [25] Global Patterns of Care for HER2/Neu Overexpressing Breast Cancer
    Chavarri-Guerra, Y.
    Liedke, P.
    Symecko, H.
    Moy, B.
    Higgins, M.
    St Louis, J.
    Finkelstein, D.
    Goss, P.
    [J]. CANCER RESEARCH, 2011, 71
  • [26] Her2/neu in local metastases and primary focus of breast cancer
    Sazonov, S.
    Konyshev, K.
    [J]. VIRCHOWS ARCHIV, 2015, 467 : S55 - S55
  • [27] Association between HER2/neu overexpression and calcifications in breast cancer
    Christy, C. J.
    Rishi, M.
    Schwartz, J.
    Grube, B. J.
    Bossuyt, V.
    Philpotts, L.
    DiGiovanna, M. P.
    Tavassoli, F.
    Lannin, D. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Prognostic and predictive value of HER2/neu oncogene in breast cancer
    Masood, S
    Bui, MM
    [J]. MICROSCOPY RESEARCH AND TECHNIQUE, 2002, 59 (02) : 102 - 108
  • [29] HER2/neu multicentric study in breast cancer at the Comunidad Valenciana
    Felipe-Ponce, V.
    Rubio, L.
    Rubio-Alcala, M. C.
    Sentamans, C. Villalba
    Garcia, A.
    Martinez, M. J. Artes
    Vera-Sempere, F. J.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2007, 9 (05): : 687 - 687
  • [30] Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene
    Harbeck, Nadia
    Pegram, Mark D.
    Rueschoff, Josef
    Moebus, Volker
    [J]. BREAST CARE, 2010, 5 : 3 - 7
12345